Applied Spectral Imaging (ASI) Inc. and WaveSense Inc. have partnered to deliver an integrated cell-capturing solution and computerized instrument to detect, image and analyze captured cells. Under the agreement, both companies will market ASI’s GenASIs imaging and analysis instrument and WaveSense’s EpiSEP cell recovery and enrichment solution. When combined, the platforms can perform semi-automated fluorescence in situ hybridization (FISH) analysis of paramagnetic labeled target cells, and are suitable for molecular pathology and cytogenetics applications. “Personalized medicine challenges laboratories to continuously evolve and expand their molecular pathology applications rapidly and cost-effectively,” said WaveSense CEO Chris Feistel. “WaveSense and ASI platforms provide a straightforward, versatile environment for optimizing existing applications or implementing new applications.” For more information, visit: www.spectral-imaging.com or www.wavesense.net